Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL - Get Free Report) were up 7.2% during trading on Wednesday . The stock traded as high as $8.55 and last traded at $8.60. Approximately 476,510 shares were traded during mid-day trading, a decline of 62% from the average daily volume of 1,250,416 shares. The stock had previously closed at $8.02.
Analyst Upgrades and Downgrades
A number of research firms have commented on AVXL. HC Wainwright restated a "buy" rating and set a $42.00 price target on shares of Anavex Life Sciences in a research note on Monday. D. Boral Capital reaffirmed a "buy" rating and issued a $46.00 target price on shares of Anavex Life Sciences in a research report on Monday.
Get Our Latest Research Report on Anavex Life Sciences
Anavex Life Sciences Stock Up 1.7 %
The stock has a fifty day moving average of $8.84 and a 200-day moving average of $8.43. The stock has a market capitalization of $708.58 million, a PE ratio of -15.15 and a beta of 0.80.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last announced its quarterly earnings data on Wednesday, February 12th. The biotechnology company reported ($0.14) EPS for the quarter, beating analysts' consensus estimates of ($0.17) by $0.03. Equities research analysts expect that Anavex Life Sciences Corp. will post -0.69 EPS for the current year.
Institutional Investors Weigh In On Anavex Life Sciences
Several institutional investors have recently added to or reduced their stakes in AVXL. Vermillion Wealth Management Inc. acquired a new stake in Anavex Life Sciences during the fourth quarter worth approximately $34,000. Tower Research Capital LLC TRC raised its stake in Anavex Life Sciences by 102.0% during the 4th quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 1,708 shares in the last quarter. Berkshire Money Management Inc. acquired a new position in Anavex Life Sciences in the fourth quarter valued at $107,000. Prudential Financial Inc. purchased a new position in shares of Anavex Life Sciences during the fourth quarter worth about $109,000. Finally, Fiduciary Alliance LLC acquired a new stake in shares of Anavex Life Sciences during the fourth quarter worth about $119,000. Hedge funds and other institutional investors own 31.55% of the company's stock.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
Featured Articles
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
